Lexeo Therapeutics (LXEO)

Profile

Full Name

Lexeo Therapeutics, Inc.

Ticker Symbol

LXEO

Exchange

NASDAQ

Sector

Healthcare

Industry

Biotechnology

Country

United States

IPO

November 3, 2023

Indexes

Not included

Website

http://www.lexeotx.com

Employees

72

Key Details

Price

$2.55(+19.16%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

-

Annual EPS

-$3.09(+75.08% YoY)

PE ratio

-

Next earnings date

May 9, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$2.55
LXEO price is $2.55

30-Day Relative Volume

0.64
LXEO 30-day relative volume is 0.64

Price Performance

Price Most recent change

+19.16%
LXEO price was up +19.16% on Apr 15, 2025

Price YTD change

-61.25%
LXEO price is down -61.25% since January 1st

Price 1-year change

-79.15%
LXEO price is down -79.15% year-on-year

Price 3-year change

-
LXEO price 3-year change is unknown

Price Range

Price All-time high

$22.33
LXEO price is currently -88.58% below its historical high of $22.33

Price 3-year low

$1.45
LXEO price is currently +75.86% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$84.65M
LXEO market capitalization is $84.65 million

Market cap 3-year change

-
LXEO market capitalization 3-year change is unknown

Market cap All-time high

$618.05M
LXEO market capitalization is currently -86.30% below its historical high of $618.05 million

Market cap sector rank

46.38%
LXEO market capitalization is higher than 46.38% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+0.76%
LXEO shares outstanding is up +0.76% year-on-year

Shares Outstanding 3-Year Change

-
LXEO shares outstanding 3-year change is unknown

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

1.95
LXEO beta is 1.95

200-day SMA

$7.87
LXEO price is currently -67.62% below its 200-day simple moving average

50-day SMA

$3.36
LXEO price is currently -24.19% below its 50-day simple moving average

RSI

45.57
LXEO 14-day relative strength index is 45.57

Volume

0.64
LXEO 30-day relative volume is 0.64

ATR

$0.47
LXEO average true range is $0.47

10-day Historical Volatility

252.04%
LXEO 10-day historical volatility is 252.04%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

-
LXEO annual revenue value is unknown

Revenue Analysts estimate

-
LXEO annual revenue consensus analysts' forecast is unknown

Revenue 1-year change

-
LXEO annual revenue 1-year change is unknown

Revenue Sector rank

-
LXEO annual revenue is unknown

EPS

EPS

-$3.09
LXEO annual earnings per share is -$3.09

EPS Analysts estimate

-$3.08
LXEO annual earnings per share is currently +0.19% higher than the consensus analysts' forecast

EPS 1-year change

+75.08%
LXEO annual earnings per share is up +75.08% year-on-year

EPS Sector rank

28.42%
LXEO annual earnings per share is higher than 28.42% of companies in Healthcare sector

Profit

Gross profit

-
LXEO annual gross profit value is unknown

Gross margin

-
LXEO annual gross profit margin value is unknown

Operating profit

-$105.77M
LXEO annual operating income is -$105.77 million

Operating margin

-
LXEO annual operating profit margin value is unknown

Net income

-$98.33M
LXEO annual net profit is -$98.33 million

Net margin

-
LXEO annual net profit margin value is unknown

Expenses

Total expenses

$105.77M
LXEO annual total expenses is $105.77 million

Operating expenses

$105.77M
LXEO annual total operating expenses is $105.77 million

Cost of goods sold

-
LXEO annual cost of goods sold value is unknown

Selling, general & administrative expenses

$31.68M
LXEO annual SGA is $31.68 million

Depreciation and amortization

$2.00M
LXEO annual depreciation & amortization is $2.00 million

Interest expense

$137.00K
LXEO annual interest expense is $137.00 thousand

Income tax

$0.00
LXEO annual income tax is $0.00

EBIT & EBITDA

EBIT

-$98.20M
LXEO annual earnings before interest & taxes is -$98.20 million

EBITDA

-$96.19M
LXEO annual EBITDA is -$96.19 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$146.94M
LXEO annual total assets is $146.94 million

Non current assets

$20.82M
LXEO annual long term assets is $20.82 million

Current assets

$126.12M
LXEO annual total current assets is $126.12 million

Cash and cash equivalents

$35.01M
LXEO annual cash & cash equivalents is $35.01 million

Accounts receivable

-
LXEO annual accounts receivable value is unknown

Inventory

-
LXEO annual inventory value is unknown

Liabilities

Total liabilities

$30.10M
LXEO annual total liabilities is $30.10 million

Long term liabilities

$7.25M
LXEO annual total long term liabilities is $7.25 million

Current liabilities

$22.85M
LXEO annual total current liabilities is $22.85 million

Accounts payable

$6.42M
LXEO annual accounts payable is $6.42 million

Debt

Total debt

$9.92M
LXEO annual total debt is $9.92 million

Total debt 1-year change

-14.73%
LXEO annual total debt is down -14.73% year-on-year

Long term debt

$7.25M
LXEO annual long term debt is $7.25 million

Short term debt

$2.67M
LXEO annual short term debt is $2.67 million

Equity & Capital

Shareholders equity

$116.84M
LXEO annual stockholders equity is $116.84 million

Book value

$116.84M
LXEO annual book value is $116.84 million

Retained earnings

-$280.17M
LXEO annual retained earnings is -$280.17 million

Working capital

$103.28M
LXEO annual working capital is $103.28 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

-$81.15M
LXEO annual cash flow from operations is -$81.15 million

Cash from operations 1-year change

-36.4%
LXEO annual cash flow from operations is down -36.4% year-on-year

Cash from investing

-$94.08M
LXEO annual cash flow from investing activities is -$94.08 million

Cash from investing 1-year change

-56916.36%
LXEO annual cash flow from investing activities is down -56916.36% year-on-year

Cash from financing

$88.78M
LXEO annual cash flow from financing activities is $88.78 million

Cash from financing 1-year change

-14.47%
LXEO annual cash flow from financing activities is down -14.47% year-on-year

CAPEX

CAPEX

-
LXEO annual capital expenditures value is unknown

CAPEX 1-year change

-
LXEO annual capital expenditures 1-year change is unknown

Free Cash Flow

Free cash flow

-$81.63M
LXEO annual free cash flow is -$81.63 million

Free cash flow 1-year change

-36.83%
LXEO annual free cash flow is down -36.83% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

-
LXEO annual gross profit margin value is unknown

Operating margin

-
LXEO annual operating profit margin value is unknown

Net margin

-
LXEO annual net profit margin value is unknown

ROA & ROE

ROA

-66.92%
LXEO annual return on assets is -66.92%

ROE

-84.16%
LXEO annual return on equity is -84.16%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
LXEO price to earnings ratio value is unknown

PE ratio Sector rank

-
LXEO price to earnings ratio is unknown

PB Ratio

PB ratio

0.72
LXEO price to book ratio is 0.72

PB ratio Sector rank

36.95%
LXEO price to book ratio is higher than 36.95% of companies in Healthcare sector

PS Ratio

PS ratio

-
LXEO price to sales ratio value is unknown

PS ratio Sector rank

-
LXEO price to sales ratio is unknown

Enterprise value

Enterprise value

$59.56M
LXEO enterprise value is $59.56 million

Enterprise value Sector rank

43.67%
LXEO enterprise value is higher than 43.67% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-0.62
LXEO EV/EBITDA is -0.62

EV/EBITDA Sector rank

49.17%
LXEO EV/EBITDA is higher than 49.17% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

5.52
LXEO annual current ratio is 5.52

Quick ratio

-
LXEO annual quick ratio value is unknown

Leverage

Debt to equity

0.08
LXEO annual debt to equity ratio is 0.08

Interest coverage ratio

-716.76
LXEO annual interest coverage ratio is -716.76

Risk & Stability

Piotroski F-Score

-
LXEO piotroski f-score value is unknown

Altman Z-Score

-
LXEO altman z-score value is unknown

Analyst ratings

Recent major analysts updates

Apr 8, 25 HC Wainwright & Co.
Buy
Apr 8, 25 Chardan Capital
Buy
Mar 26, 25 HC Wainwright & Co.
Buy
Mar 25, 25 RBC Capital
Outperform
Mar 25, 25 Chardan Capital
Buy
Mar 24, 25 Leerink Partners
Outperform
Jan 21, 25 RBC Capital
Outperform
Nov 14, 24 HC Wainwright & Co.
Buy
Nov 13, 24 Leerink Partners
Outperform
Nov 13, 24 Chardan Capital
Buy

Institutional Ownership

Similar stocks

GALT logo
Galectin Therapeutics (GALT)
CCCC logo
C4 Therapeutics (CCCC)
SY logo
So-Young International (SY)
CRVO logo
CervoMed (CRVO)
OCX logo
OncoCyte (OCX)
KYTX logo
Kyverna Therapeutics (KYTX)
BDSX logo
Biodesix (BDSX)
QIPT logo
Quipt Home Medical (QIPT)
SRZN logo
Surrozen (SRZN)
  • What is the ticker symbol for Lexeo Therapeutics?
  • Does Lexeo Therapeutics pay dividends?
  • What sector is Lexeo Therapeutics in?
  • What industry is Lexeo Therapeutics in?
  • What country is Lexeo Therapeutics based in?
  • When did Lexeo Therapeutics go public?
  • Is Lexeo Therapeutics in the S&P 500?
  • Is Lexeo Therapeutics in the NASDAQ 100?
  • Is Lexeo Therapeutics in the Dow Jones?
  • When was Lexeo Therapeutics's last earnings report?
  • When does Lexeo Therapeutics report earnings?
  • Should I buy Lexeo Therapeutics stock now?

What is the ticker symbol for Lexeo Therapeutics?

The ticker symbol for Lexeo Therapeutics is NASDAQ:LXEO

Does Lexeo Therapeutics pay dividends?

No, Lexeo Therapeutics does not pay dividends

What sector is Lexeo Therapeutics in?

Lexeo Therapeutics is in the Healthcare sector

What industry is Lexeo Therapeutics in?

Lexeo Therapeutics is in the Biotechnology industry

What country is Lexeo Therapeutics based in?

Lexeo Therapeutics is headquartered in United States

When did Lexeo Therapeutics go public?

Lexeo Therapeutics's initial public offering (IPO) was on November 3, 2023

Is Lexeo Therapeutics in the S&P 500?

No, Lexeo Therapeutics is not included in the S&P 500 index

Is Lexeo Therapeutics in the NASDAQ 100?

No, Lexeo Therapeutics is not included in the NASDAQ 100 index

Is Lexeo Therapeutics in the Dow Jones?

No, Lexeo Therapeutics is not included in the Dow Jones index

When was Lexeo Therapeutics's last earnings report?

Lexeo Therapeutics's most recent earnings report was on Mar 24, 2025

When does Lexeo Therapeutics report earnings?

The next expected earnings date for Lexeo Therapeutics is May 9, 2025

Should I buy Lexeo Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page